Vanquish Oncology has begun enrollment in the first human clinical trial for a procaspase activating agent. The trial, “Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies”, is a phase I, dose escalation study being run at the University of Illinois Cancer Center. For more information about the trial please see https://www.clinicaltrials.gov or contact the personnel below at the University of Illinois Cancer Center or at the Johns Hopkins Kimmel Cancer Center.
University of Illinois Cancer Center
Oana C. Danciu, M.D.
Alisha Williams, R.N.
Johns Hopkins Kimmel Cancer Center
Matthias Holdhoff, M.D.